WOONSOCKET — CVS Caremark Corp. is paying a $20-million penalty to the Securities and Exchange Commission (SEC) to resolve an investigation into certain corporate actions taken in 2009 — including some...

WOONSOCKET — CVS Caremark Corp. is paying a $20-million penalty to the Securities and Exchange Commission (SEC) to resolve an investigation into certain corporate actions taken in 2009 — including some public disclosures, securities transactions by current and former employees and aspects of its accounting methods related to its 2008 acquisition of the Longs Drug Stores chain.

In a news release confirming the penalty payment, the Woonsocket-based corporation Friday said that it is entering into the settlement on a “no admit or deny basis,” which means there is no admission or denial of any wrongdoing.

A CVS spokesperson declined to elaborate on the prepared statement, which is sparse on the details of the SEC investigation.

The SEC also declined comment, stating that its investigations are private.

CVS Caremark stated that the settlement will “resolve a number of alleged violations of the Securities Act of 1933 and the Securities Exchange Act of 1934, including certain anti-fraud provisions of those statutes.”

The statement says that the SEC investigation was launched in 2011 and “focused on events that occurred in the third and fourth quarters of 2009.”

It states that the investigation looked into “certain public disclosures made by the Company, transactions in the Company’s securities by certain current and former employees and certain aspects of the purchase accounting adjustment related to the October 2008 Longs Drug Stores acquisition.”

According to reports posted on its website, CVS’s net revenue in 2012 was about $123 billion.

“We are pleased to be taking this important step to close the chapter on these matters from 2009 and look forward to resolving the SEC investigation in the near future,” stated Thomas M. Moriarty, Executive Vice President and General Counsel of CVS Caremark.

“CVS Caremark remains committed to complying with all applicable laws and regulations. We will continue to focus on driving value for our customers and shareholders through our distinctive integrated pharmacy model.”

The company said that the settlement, which was reached following “extensive discussions” with the SEC in recent months, remains subject to final documentation and approval of the commission and federal court.

It also stated that because the $20 million civil penalty was reserved in CVS Caremark’s financial statements, the corporation will not have to restate its earnings for any reporting period.

CVS Caremark’s public statement on the settlement can be read at: http://bit.ly/1ehrhlY